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Abstract
Background: Platinum-based regimens are the treatments of choice in ovarian cancer, which remains the leading
cause of death from gynecological malignancies in the Western world. The aim of the present study was to
compare the advantages and limits of a conventional chemosensitivity test with those of new biomolecular
markers in predicting response to platinum regimens in a series of patients with peritoneal carcinomatosis from
ovarian cancer.
Methods: Fresh surgical biopsy specimens were obtained from 30 patients with primary or recurrent peritoneal
carcinomatosis from ovarian cancer. ERCC1, GSTP1, MGMT, XPD, and BRCA1 gene expression levels were determined
by Real-Time RT-PCR. An in vitro chemosensitivity test was used to define a sensitivity or resistance profile to the
drugs used to treat each patient.
Results: MGMT and XPD expression was directly and significantly related to resistance to platinum-containing
treatment (p = 0.036 and p = 0.043, respectively). Significant predictivity in terms of sensitivity and resistance was
observed for MGMT expression (75.0% and 72.5%, respectively; p = 0.03), while high predictivity of resistance
(90.9%) but very low predictivity of sensitivity (37.5%) (p = 0.06) were observed for XPD. The best overall and
significant predictivity was observed for chemosensitivity test results (85.7% sensitivity and 91.3% resistance; p =
0.0003).
Conclusions: The in vitro assay showed a consistency with results observed in vivo in 27 out of the 30 patients
analyzed. Sensitivity and resistance profiles of different drugs used in vivo would therefore seem to be better
defined by the in vitro chemosensitivity test than by expression levels of markers.
Background
The selection of a chemotherapy regimen for individual
tumors is normally based on histology, clinical charac-
teristics of the patient and retrospective evidence from
randomized clinical trials. However, patients with the
same tumor histotype, especially in solid malignancies,
often respond differently to the same chemotherapy
regimen due to intertumor heterogeneity. Despite
knowledge of such heterogeneity, chemotherapy is still
largely empirically planned, and the acquisition of
information for tailored therapy has consequently
become a priority in the management of cancer patients
today.
Such a goal was intensively pursued in the 1980s by
American and European research groups who developed
a number of chemosensitivity tests using fresh material
from human tumors and based on the determination of
cell proliferation (clonogenic potential and 3H-
thymidine incorporation) or total cell evaluation (dye
exclusion, sulphorhodamine blue, MTT assay and ATP
bioluminescence) [1-6]. The results obtained from the
different tests were compared and their clinical
relevance verified in a number of translational clinical
studies [5,7-10]. However, various methodological
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widespread clinical use of in vitro experimental results.
With the advent of molecular biology at the end of the
nineties, attention moved towards the search for
molecular and genetic markers involved in proliferation
and DNA repair processes that might be predictive of
response to both conventional cytotoxic and target ther-
apy drugs [11].
Platinum or platinum-based regimens are the treat-
ment of choice in ovarian cancers, which remains the
leading cause of death from gynecological malignancies
in the Western world [12]. The absence of specific
symptoms in the early stages of the disease results in
the majority of patients being diagnosed when the
disease is advanced [13]. Currently, standard primary
therapy for advanced disease involves surgical debulking
followed by platinum/taxane-based chemotherapy [14].
However, despite initially high response rates, a large
proportion of patients often experience peritoneal
relapse. Recurrent disease is treated with the same regi-
men used for first-line chemotherapy (i.e., re-induction
therapy) or with second- or third-line regimens.
Resistance to platinum alone or in combination is
multifactorial. Several studies have attempted to clarify
the mechanisms behind resistance to platinum-based
chemotherapy, whether intrinsic, as observed in colorec-
tal, prostate, breast or lung cancer, or acquired during
treatment. At present, numerous molecular pathways
are known to be involved in drug resistance, especially
that of platinum compounds. Among such pathways,
increased DNA repair and enhanced drug efflux and/or
inactivation play an important role in platinum resis-
tance and may also be instrumental in predicting patient
prognosis in a clinical setting [11,15,16].
One of the mechanisms involved in DNA repair is the
nucleotide excision repair (NER) system, which recog-
nizes helix-distorting base lesions and is presumed to be
one of the determinants of platinum resistance [15]. The
role of excision repair cross-complementation group1
(ERCC1) in the NER pathway is to incise the DNA
strand on the 5’ site relative to platinated DNA damage,
and its overexpression has been associated with clinical
resistance to cisplatin [17,18]. Xeroderma pigmentosum
group D (XPD) is another of the several genes involved
in the NER pathway. In particular, XPD opens an
approximately 30-baseline DNA segment around the
damage. It has also been reported that underexpression
of XPD in cells with transcription coupled-NER-
deficiency results in hypersensitivity to cisplatin [19].
DNA adducts at the O6-position of guanine can be
repaired by NER but also by O6 methylguanine-DNA
methyltransferase (MGMT), which is described as a
competitor of the NER mechanisms of repair [20]. Preli-
minary studies have shown that MGMT-deficient cells
are unable to repair damage and are more sensitive to
the effect induced by alkylating agents than MGMT-
proficient cells [21].
Breast cancer gene 1 (BRCA1), an essential component
of multiple DNA damage repair pathways, is considered
to be a differential modulator of survival for cells treated
with cisplatin. Preclinical and clinical studies have
reported that high levels of BRCA1 are associated with
cisplatin chemoresistance [18,22,23].
Acquired resistance to DNA adduct formation
induced by platinum compounds may be also a conse-
quence of a reduction in drug accumulation in cells due
to drug inactivation and/or enhanced efflux. The
glutathione S-transferase (GST) makes cisplatin more
anionic and more readily exported from cells by the
ATP-dependent glutathione S-conjugate export (GS-X)
pump (MRP1 or MRP2). Some, but not all, translational
studies have suggest that the glutathione metabolic
pathway may have a role in acquired drug resistance to
platinum drugs [15,24,25].
The aims of the present study were to compare the
advantages and limits of a conventional chemosensitivity
in vitro test with those of potentially interesting biomo-
lecular markers in predicting response to platinum or
platinum based regimens, in a series of patients with
peritoneal carcinomatosis from ovarian cancer.
Patients and Methods
Patients
Thirty-two patients with peritoneal carcinomatosis from
primary advanced (7 cases) or recurrent (25 cases) ovar-
ian cancer were recruited for the in vitro chemosensitiv-
ity assay and for analysis of biomarkers potentially
predictive of resistance to platinum compounds. Patients
underwent surgical resection at Pierantoni Hospital in
Forlì and or at Bentivoglio Hospital in Bologna. Inclusion
criteria were histological confirmation of advanced or
recurrent ovarian cancer and pre- or a postsurgery che-
motherapy based on a platinum compound (carboplatin/
taxol or cisplatin/adriamycin or carboplatin/gemcitabine
or carboplatin as monochemotherapy). It was not possi-
ble to perform the in vitro chemosensitivity test in
2 patients due to insufficient material. The remaining
30 patients all had serous tumor subtypes. Median age of
patients was 60 ± 13.3 years (range 32-81).
Informed consent was obtained before surgical
treatment and patients were required to be accessible
for follow-up. The study protocol was approved by the
Local Ethics Committee. In order to evaluate the corre-
lation between gene expression or in vitro chemosensi-
tivity and clinical response to platinum-containing
treatment, patients were subdivided into responders
(partial or complete clinical response and stable disease)
or non-responders (progressive disease).
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Clinical response was evaluated by measuring circulating
CA125 levels before each treatment cycle. Tumor
imaging was performed every three cycles using ultraso-
nography or CT/MRI scans. The same clinical and
instrumental evaluation was carried out every 3 months
after the end of treatment.
Sample Collection
Immediately after surgical resection, tumor specimens
were sampled and analyzed (under sterile conditions) by
a pathologist to confirm the tumor representativity of
the samples. A part of the tissue was then stored in
RNAlater
® Tissue Collection (Invitrogen, Carlsbad, CA)
at a temperature of +4°C to preserve mRNA integrity,
while another part was used immediately for the chemo-
sensitivity test.
Real-Time RT-PCR Analysis
Total RNA was extracted from fresh surgical biopsies
using TRIzol
® Reagent within 2 or 3 hours of surgery,
in accordance with the manufacturer’s instructions
(Invitrogen). Reverse transcription (RT) reactions were
performed in a 20-μl volume containing 800 ng of total
RNA using iScript TM cDNA Synthesis kit (Bio-Rad
Laboratories, Hercules, CA) and analyzed by Real Time
RT-PCR (MyiQ System, Bio-Rad) to detect the expres-
sion of the genes MGMT, BRCA1, ERCC1, GSTP1,a n d
XPD. Primers for mRNA amplification were designed
using Beacon Designer Software (version 4, BioRad) and
sequences are listed in Table 1. The standard reaction
volume was 25 μl containing 2 μl of cDNA template,
1 × SYBR Green Mix and 5 μM of forward and reverse
primers. The mixture was subjected to the following
cycling conditions: 95°C for 1 min and 30 s, followed by
40 cycles of amplification for 15 s at 95°C and 30 s at
59°C (for XPD) or 60°C (for MGMT, BRCA1, ERCC1,
GSTP1, b2-microglobulin, and hypoxanthine phosphori-
bosyltransferase (HPRT)). The amount of mRNA of
each marker was normalized to the endogenous
references b2-microglobulin and HPRT using Gene
Expression Macro Software (Version 1.1) (BioRad).
Commercial RNA control derived from a pool of normal
ovarian tissue mRNA was used as calibrator.
The efficiency of amplification, which never exceeded
5% variability in the different experiments, was used to
determine the relative expression of mRNA and was
calculated using Gene Expression Macro Software (Ver-
sion 1.1) (BioRad). The reproducibility of Real-Time
PCR results was verified in triplicate, and the coefficient
of variation (CV), calculated from the three Ct values,
was always < 1.5%.
In vitro Chemosensitivity Test
A cell suspension was obtained after 4-16 hours of enzy-
matic digestion of fresh tumor tissue. Cells were
counted and plated at a density of 1,000,000 cells/well
in 96-well flat-bottomed microtiter plates (100 μlo fc e l l
suspension/well). Experiments were run in octuplicate.
The optical density of treated and untreated cells was
determined at a wavelength of 540 nm using a fluores-
cence plate reader.
Cells were exposed for 72 hours to 1, 10 and 100 μM
of cisplatin or adriamycin; 8, 80 and 800 μM of carbo-
platin; 4, 40 and 400 μM of gemcitabine; and 0.6, 6 and
60 μM of taxol. Drugs were used at concentrations
corresponding to peak plasma levels and were also
tested at doses equivalent to one-tenth of and tenfold
the peak plasma value. Drug activity was assessed by
sulforhodamine B assay according to the method of
Skehan et al [4]. PC3 tumor cell line, for which the
dose-response curve to the anticancer agents used is
known, was used as an internal control in all single
experiments performed.
Statistical Analysis
The relationship between continuous (gene expression)
and dichotomous variables was analyzed using a non-
parametric ranking statistic (median test) [26].
Spearman’s correlation coefficient (rs) was used to inves-
tigate the correlation between the mRNA expression of
different genes, such as MGMT, BRCA1, ERCC1, GSTP1
and XPD, considered as continuous variables. Receiver
operating characteristic (ROC) analysis was performed
Table 1 Oligonucleotides used for Real-Time PCR
Gene name 5’ to 3’ forward primer 5’ to 3’ reverse primer Annealing temperature
MGMT tcttcaccatcccgttttcc attgcctctcattgctcctc 60°C
BRCA1 gctcgctgagacttcctg gataaatccatttctttctgttcc 60°C
ERCC1 tcagtcaacaaaacggacagtcag tccttgggttctttcccagagc 60°C
GSTP1 aacatgaggcgggcaag gttgtagtcagcgaaggag 60°C
XPD aagcaggagggcgagaag cctcatagaatcggcagtgg 59°C
HPRT agactttgctttccttggtcagg gtctggcttatatccaacattcg 60°C
Beta2-microglobulin cgctactctctctttctggc agacacatagcaattcaggaat 60°C
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considered an algorithm that renders a single composite
score using the linear predictor fitted from a binary
regression model. This algorithm has been justified to
be optimal under the linearity assumption [27,28] that
the ROC curve is maximized (i.e., best sensitivity) at
every threshold value. The chi-square test was used to
compare dichotomous variables.
All statistical analyses were performed with SAS
Statistical Software (version 9.1, SAS Institute Inc., Cary,
NC). Two-sided p values < 0.05 were considered
significant.
Results
The analysis of the comparison between in vitro and
clinical results was performed on 30 cases with serous
tumors. Fifteen patients obtained complete cytoreduc-
tion, 6 had minimal residual disease, 4 had maximum
residual disease, and the remaining 5 had unresectable
disease. The majority of patients (56%) underwent car-
boplatin/taxol chemotherapy, 20% received cisplatin/
adriamycin, 10% carboplatin as monochemotherapy, and
6% carboplatin/gemcitabine or carboplatin/taxol/
gemcitabine (Table 2).
Gene Expression Analysis
Of the 5 genes analyzed, MGMT and XPD expression
was directly and significantly related to resistance to cis-
platin-including regimens (p = 0.03 and p = 0.04,
respectively) (Table 3). In particular, median expression
values of MGMT and XPD in tumors were about four-
fold higher in non-responders than in responders.
All 5 genes were generally poorly correlated with each
other; with correlation coefficients (rs)r a n g i n gf r o m
0.577 to 0.074. In particular, of the two genes whose
expression was maximally predictive of sensitivity or
resistance to clinical treatment, XPD was not signifi-
cantly related to ERCC1 or GSTP1, and showed border-
line clinical significance with MGMT.T h es e c o n d ,
MGMT, was significantly related, albeit with a very poor
correlation coefficient, to the other four genes (Table 4).
The accuracy in predicting sensitivity or resistance to
clinical treatment was analyzed for each single gene and
for combinations of genes not significantly correlated
with each other. Results were expressed as the area
under the curve (AUC) and in terms of sensitivity,
specificity and overall accuracy (Table 5). AUC values
were maximum for MGMT (0.73; 95% CI 0.53-0.94) and
XPD (0.70; 95% CI 0.48-0.91), and different gene combi-
nations did not provide more accurate information.
Only the 5 markers considered together slightly
improved the AUC value (0.79; CI 0.62-0.97).
These results were paralleled by those expressed as
overall accuracy: 78.5% and 75% for MGMT and XPD,
respectively and 75% for the 5 markers considered
together. XPD expression was characterized by the high-
est sensitivity (89.4%) but very low specificity (44.4%),
while MGMT showed both high sensitivity (78.9%) and
specificity (77.8%).
In Vitro Chemosensitivity Test
In parallel, a molecular profile of chemosensitivity to all
the drugs used in the clinical treatment was generated
for each tumor. Patients were subdivided into responders
Table 2 Tumor and patient characteristics and treatment
information of the case series
Characteristics No. patients
Cancer
Primary 7
Recurrent 23
Histological type
Serous 30
Results of cytoreduction
CC0 15
CC1 6
CC2 4
Unresectable 5
Peritoneal Cancer Index (mean and range) 22.7 (6-39)
Type of treatment
Carboplatin/taxol 17
Cisplatin/adriamicin 6
Carboplatin 3
Carboplatin/gemcitabine 2
Carboplatin/taxol/gemcitabine 2
CC0, complete cytoreduction; CC1, minimal residual disease; CC2, maximum
residual disease
Table 3 Tumor gene expression to platinum-containing
treatment in responders and non-responders
Median expression values (range)
Gene Total patients Responders Non-responders p
MGMT 0.90 (0-20.0) 0.57 (0-2.2) 2.0 (0-20.0) 0.03
XPD 0.80 (0.027-12.4) 0.52 (0.027-2.0) 1.9 (0.11-12.4) 0.04
BRCA1 2.60 (0-87.4) 1.73 (0.20-6.47) 3.0 (0-87.4) 0.59
ERCC1 1.50 (0.47-15.0) 2.30 (0.7-7.02) 1.4 (0.47-15.0) 0.93
GSTP1 1.75 (0.15-45.0) 1.47 (0.15-7.5) 1.7 (0.71-45.0) 0.65
Table 4 Correlation between XPD or MGMT and other
marker expression
XPD BRCA1 ERCC1 GSTP1
rs pr s pr s pr s p
XPD 0.476 0.007 0.074 0.696 0.307 0.099
MGMT 0.355 0.054 0.548 0.002 0.432 0.017 0.577 0.001
rs, correlation coefficient
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or non-responders (progressive disease), to evaluate the
correlation between in vitro chemosensitivity assay and
clinical response to platinum-containing treatments
(Table 6). Seventeen patients (56.6%) were treated with
carboplatin and taxol, of whom 6 had primary advanced
and 11 recurrent ovarian cancer. We did not observe any
significant differences in either in vitro or clinical sensi-
tivity or resistance between primary and recurrent can-
cers. Considering the 2 subgroups together, concordance
between in vitro results and clinical response was
observed in 14 cases (3 in terms of sensitivity, 11 in
terms of resistance). The 3 cases in whom there was no
correspondence between in vitro and in vivo results were
all in vitro sensitive to one drug (carboplatin or taxol);
two showed clinical progression and one stable disease
(Table 6). Similarly, in the subgroup of 6 patients treated
with cisplatin and adriamycin, 3 were in vitro-sensitive to
both drugs and showed a clinical response, while 3 were
in vitro resistant to both drugs and showed disease pro-
gression. Patients treated with carboplatin (3 cases: 1 pri-
mary and 2 recurrent), carboplatin and gemcitabine (2
cases), or carboplatin, taxol and gemcitabine (2 cases)
were in vitro resistant to all the drugs and all had disease
progression.
Comparison between the two In Vitro Approaches
Results of the clinical response predictivity of the most
relevant markers, considered singly or in combination,
and of the in vitro chemosensitivity test are shown in
Table 7. Significant predictivity in terms of sensitivity
and resistance to the different cisplatin-based regimens
was observed for MGMT expression (75.0% and 72.5%,
respectively; p = 0.03), while high predictivity with
regard to resistance (90.9%), but very low predictivity in
terms of sensitivity (37.5%) (p = 0.06) were observed for
XPD. The combined analysis of the five markers gave
the highest predictivity with regard to resistance but
Table 5 Sensitivity and specificity of individual markers
or their combination in predicting response to treatment
AUC Cut-
off ≥
Sensitivity
(%)
Specificity
(%)
Overall
accuracy (%)
MGMT 0.73 0.72 78.9 77.8 78.5
XPD 0.70 0.22 89.4 44.4 75.0
BRCA1 0.62 2.43 63.1 66.6 64.3
ERCC1 0.56 1.37 73.7 44.4 64.3
GSTP1 0.57 1.09 63.1 55.5 60.7
MGMT + XPD 0.67 - 63.1 55.5 60.7
XPD + ERCC1 0.69 - 73.9 44.4 67.8
XPD + GSTP1 0.69 - 78.9 44.4 67.8
Five markers
together
0.79 - 74.0 77.8 75.0
AUC, area under the curve
Table 6 Correspondence between in vitro activity and
clinical efficacy in individual tumors
In vitro results Clinical results
Primary Carboplatin/taxol
S/S S
R/S S
R/R R
R/R R
R/R R
R/R R
Carboplatin
RR
Recurrent Carboplatin/taxol
S/S S
R/S R
S/S S
S/R R
R/R R
R/R R
R/R R
R/R R
R/R R
R/R R
R/R R
Cisplatin/adriamycin
R/R R
S/S S
S/S S
S/S S
R/R R
R/R R
Carboplatin
RR
RR
Carboplatin/gemcitabine
R/R R
R/R R
Carboplatin/taxol/gemcitabine
R/R/R R
R/R/R R
S, sensitive; R, resistant
Table 7 Predictivity of clinical response by different
biomarkers or in vitro chemosensitivity test
Sensitivity (%) Resistance (%) p
Markers
MGMT 75.0 72.5 0.03
XPD 37.5 90.9 0.06
Five markers 33.3 100 0.07
Chemosensitivity test 85.7 91.3 0.0003
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33.3%, respectively; p = 0.07).
T h eb e s to v e r a l la n ds i g n i f i c a n tp r e d i c t i v i t yw a s
observed for the in vitro chemosensitivity test results
(85.7% sensitivity and 91.3% resistance, p = 0.0003). The
markers were not effective in predicting resistance or
sensitivity to treatment with platinum when recurrent
(23) or primary (7) patients were analyzed. Conversely,
the chemosensitivity test maintained a significant ability
to predict response to chemotherapy in both series of
patients.
Discussion
Prediction of response to drugs at preclinical level could
help physicians to plan more effective tailored therapy
for individuals, reduce undesirable drug toxicity and
lower the cost of health care. In ovarian cancer, despite
the heterogeneity of treatments available for peritoneal
carcinomatosis, the majority of patients receive plati-
num-containing chemotherapy in either first- or second-
and third-line settings. The use of the re-induction ther-
apy in peritoneal carcinomatosis underlines the impor-
tance of studying these patients in terms of preclinical
evaluation for response to platinum-containing treat-
ments in order to avoid inactive treatments caused by
acquired resistance.
There is a large body of literature highlighting a num-
ber of biomarkers as potential candidates for predicting
resistance or sensitivity to treatment [11,17-22,29-33]. In
the present study, we investigated the role of potentially
interesting biomolecular markers and evaluated the rele-
vance of a conventional in vitro chemosensitivity test for
predicting clinical response to platinum-based regimens
in patients with peritoneal carcinomatosis from ovarian
cancer.
Among the markers studied, MGMT and XPD gene
expression proved effective in predicting response to
platinum-containing therapy. The MGMT gene showed
good prediction with regard to both sensitivity and
resistance, which, is in contrast to results obtained by
Codegoni and coworkers who failed to find any relation
between MGMT expression, detected by northen blot
analysis, and response to platinum-based therapy in
patients with primary ovarian cancer [34]. XPD expres-
sion was strongly correlatedw i t hd r u gr e s i s t a n c eb u t
weakly associated with drug sensitivity. These results are
in agreement with those of Aloyz and coworkers who
observed a relationship between XPD overexpression
and resistance to alkylating agents in human tumor cell
lines [35].
In our study the highest predictivity was observed for
the in vitro chemosensitivity test used to evaluate drug
activity. A strong correlation between in vitro results
and clinical response was observed in 27 out of the 30
patients analyzed, with a predictivity of 85.7% in terms
of sensitivity and of 91.3% in terms of resistance. The
important predictive relevance of the in vitro chemosen-
sitivity test confirms findings published by other authors
on a large number of solid and hematologic tumors
[9,36-40].
Evaluation of the two analytical approaches highlights
the lower cost and higher accuracy, but also the longer
execution time and larger amount of tumor material
required by the chemosensitivity test compared to Real-
Time PCR determination of biomarkers, which gives
rapid results using only a few nanograms of RNA.
Conclusions
In conclusion, it no longer appears ethical to treat
patients with drugs to which resistance can be predicted
by preclinical experimental techniques in more than
90% of cases. One solution might therefore be to use
tumor material from ovarian carcinomatosis as a model
for in vitro phase II studies to explore the antitumor
activity of conventional and novel drugs, singly or in
combination.
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